Figure 3.

Therapeutic effect of pIL-12 against subcutaneous murine melanoma. (A) Tumor development in animals vaccinated with pIL-12. (B) Combined treatment with pIL-12 and drug 7A. (C) Increased survival of IL-12 and IL-12 + drug 7A-treated mice. C57Bl/6 mice were injected with 5 x 10⁴ B16F10-Nex2 tumor cells, and on day 2, the animals were vaccinated with pIL-12 or plasmid with drug 7A. Drug 7A was administered i.p. three times a week, 10 µM per animal. Control groups were vaccinated with empty plasmid. For each group, n = 10; Kaplan-Meier test for the control and vaccinated groups with pIL-12 (P = .023) or pIL-12 + drug 7A (P = .009).